NOTE: All animal protocols were approved by the Johns Hopkins University Animal Care and Use Committee.
1. Animal Preparation
2. Measurement of Diffusion Factor for Carbon Monoxide (DFCO)
Figure 1 shows the DFCO measurements from the adult mice in groups A, B, C, D, E, and F. There were significant decreases with both the Aspergillus and influenza infections, as well as significant decreases in the fibrotic, emphysematous, and acute lung injury models. Figure 2 shows the Group G developmental changes in DFCO over time as the mice age from 2-6 weeks. There was a slight but significant increase with lung development over this time course. The effect of using a smaller inflation volume was also quite apparent at the 6 week time point. There was a tendency for the females to have a slightly higher DFCO, but this was only significant at the 5 week time point.
Group | Pathology or Condition | Comments |
A | C57BL/6 controls (8-10 weeks), n = 6 | Healthy mice |
B | C57BL/6 mice given 25 TCID50 of influenza A virus (PR8) intranasally, n = 10 | Influenza model, studied 6 and 8 days post-infection |
C | C57Bl/6 mice given 5.4 U pancreatic elastase intratracheally, n = 6 | Emphysema model10,13 studied 21 days after elastase challenge |
D | C57BL/6 mice given 0.05 U bleomycin intratracheally, n = 6 | Fibrosis model14 studied 14 days after bleomycin challenge |
E | CFTR null controls and those infected with aerosol inhalation of Aspergillus fumigatus (strain AF293), n = 6 | Fungal infection model11,17 studied 12 days after fungal infection |
F | C57BL/6 mice given 3 µg/g BW LPS (Escherichia coli) intratracheally, n = 6 | Acute Lung Injury (ALI) model15 studied on days 1 and 4 after the LPS insult |
G | C57BL/6 male mice at 2 to 6 weeks of age, n = 5 at each age | Lung development model |
Table 1: Listing of the different mouse models where the DFCO was measured.
Figure 1: Measurement of DFCO in the control C57BL/6 mice (Group A) and in each of the 5 different pathologic models. Shown are results 6 and 8 days after the PR8 influenza (Group B), 21 days after intratracheal elastase (Group C), 14 days after intratracheal bleomycin (Group D), 12 days after aspergillus infection in the CFTR null mice (Group E), and 1 and 4 days after LPS instillation (Group F). The * indicates P <0.01 vs. control, the # indicates P <0.01 between the 6 and 8 day influenza mice and the 1 and 4 day LPS mice, and the + indicates P <0.05 vs. control.
Figure 2: Measurement of DFCO in male C57BL/6 mice from 2 through 6 weeks of age (Group G). The measurements were made in all mice with an inflation volume of 0.4 ml, and in the 6 week old mice a second measurement was made with 0.8 ml. With the 0.4 ml volume, there were significant increases in DFCO between the 2 week male and those at 4, 5, and 6 weeks (P <0.05).
Gas Chromatograph | Inficon | Micro GC Model 3000A | Agilent makes a comparable model |
18 g Luer stub needle | Becton Dickenson | Several other possible vendors | |
3 mL plastic syringe | Becton Dickenson | Several other possible vendors | |
Polypropylene gas sample bags | SKC | 1 or 2 liter capacity works well | Other gas tight bags will work well |
Gas tank, 0.3% Ne,0.3% CO, balance air; (size ME) | Airgas, Inc | Z04 NI785ME3012 | This is the standard mixture used for DLCO in humans |
25 TCID50/mouse of influenza virus A/PR8 diluted in phosphate buffered saline. | |||
Porcine pancreatic elastase | Elastin Products, Owensville, MO | 5.4 U | |
Bleomycin | APP Pharmaceuticals, Schaumburg, IL | 0.25 U | |
Escherichia coli LPS8 | Sigma L2880 | 3 μg/g body weight; O55:B5 | |
Aspergillus fumigatus (isolate Af293) conidia were collected from mature colonies grown on potato dextrose agar. |
The mouse is now the primary animal used to model a variety of lung diseases. To study the mechanisms that underlie such pathologies, phenotypic methods are needed that can quantify the pathologic changes. Furthermore, to provide translational relevance to the mouse models, such measurements should be tests that can easily be done in both humans and mice. Unfortunately, in the present literature few phenotypic measurements of lung function have direct application to humans. One exception is the diffusing capacity for carbon monoxide, which is a measurement that is routinely done in humans. In the present report, we describe a means to quickly and simply measure this diffusing capacity in mice. The procedure involves brief lung inflation with tracer gases in an anesthetized mouse, followed by a 1 min gas analysis time. We have tested the ability of this method to detect several lung pathologies, including emphysema, fibrosis, acute lung injury, and influenza and fungal lung infections, as well as monitoring lung maturation in young pups. Results show significant decreases in all the lung pathologies, as well as an increase in the diffusing capacity with lung maturation. This measurement of lung diffusing capacity thus provides a pulmonary function test that has broad application with its ability to detect phenotypic structural changes with most of the existing pathologic lung models.
The mouse is now the primary animal used to model a variety of lung diseases. To study the mechanisms that underlie such pathologies, phenotypic methods are needed that can quantify the pathologic changes. Furthermore, to provide translational relevance to the mouse models, such measurements should be tests that can easily be done in both humans and mice. Unfortunately, in the present literature few phenotypic measurements of lung function have direct application to humans. One exception is the diffusing capacity for carbon monoxide, which is a measurement that is routinely done in humans. In the present report, we describe a means to quickly and simply measure this diffusing capacity in mice. The procedure involves brief lung inflation with tracer gases in an anesthetized mouse, followed by a 1 min gas analysis time. We have tested the ability of this method to detect several lung pathologies, including emphysema, fibrosis, acute lung injury, and influenza and fungal lung infections, as well as monitoring lung maturation in young pups. Results show significant decreases in all the lung pathologies, as well as an increase in the diffusing capacity with lung maturation. This measurement of lung diffusing capacity thus provides a pulmonary function test that has broad application with its ability to detect phenotypic structural changes with most of the existing pathologic lung models.
The mouse is now the primary animal used to model a variety of lung diseases. To study the mechanisms that underlie such pathologies, phenotypic methods are needed that can quantify the pathologic changes. Furthermore, to provide translational relevance to the mouse models, such measurements should be tests that can easily be done in both humans and mice. Unfortunately, in the present literature few phenotypic measurements of lung function have direct application to humans. One exception is the diffusing capacity for carbon monoxide, which is a measurement that is routinely done in humans. In the present report, we describe a means to quickly and simply measure this diffusing capacity in mice. The procedure involves brief lung inflation with tracer gases in an anesthetized mouse, followed by a 1 min gas analysis time. We have tested the ability of this method to detect several lung pathologies, including emphysema, fibrosis, acute lung injury, and influenza and fungal lung infections, as well as monitoring lung maturation in young pups. Results show significant decreases in all the lung pathologies, as well as an increase in the diffusing capacity with lung maturation. This measurement of lung diffusing capacity thus provides a pulmonary function test that has broad application with its ability to detect phenotypic structural changes with most of the existing pathologic lung models.